Recently, the anti-tumour effects of the triple PIM/PI3K/mTOR kinase inhibitor IBL-302 was interrogated following preliminary screening of hundreds of cell lines from ∼50 different tumours that revealed neuroblastoma was especially sensitive to triple kinase inhibition [153]. This evidence concerns the gene PIM1 and neuroblastoma.